BUSINESS STRATEGY:

Despite a consensus-beating earnings report in July, investor pressure for stronger financial results has been unrelenting as Eli Lily approaches one of the steepest patent cliffs in the industry. An FDA advisory committee lent the company a ray of hope Thursday. It voted 8 to 6 in favor of recommending its blockbuster antidepressant, Cymbalta, be approved for the treatment of some types of chronic pain. But a string of disappointments preceding that result has turned up the heat.
Read More